• Customer Care
  • (888) 123-4567

News

At Rise Therapeutics, we develop targeted immunological-based biologics using a unique and proprietary oral delivery platform. We design and produce unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, infection, and cancer.

BIOBUZZ: In Conversation with Gary Fanger, Ph.D., Founder, President, and CEO

Rise Therapeutics is taking on immunotherapy from a slightly different pathway – the gut microbiome.

In the context of normal human biology, the microbiome is a collection of microorganisms, including bacteria, fungi, viruses, and other microbes, that reside in various bodily habitats, including our gut. Gary Fanger, Founder, President and Chief Executive Officer of Rockville-based Rise Therapeutics, explains that the microbiome needs to be seen in light of a new organ in the body.

MCEDC: Six Montgomery County Companies Benefit from Bio Lab Pilot Project Grants

The Montgomery County Economic Development Corporation (MCEDC) awarded a total of $96,430 to six small life science companies as part of its recently completed Bio Lab Pilot Project. The project was launched in 2019 to assist local growth-stage life science companies with their wet lab and infrastructure needs. Applicants seeking financial help to build out small wet lab space less than 5,000 SF were encouraged to apply for $10 per SF of lab fit out costs, up to $30,000 per company. Project funding was provided by MCEDC and the Maryland Department of Commerce. 

Rise Therapeutics Receives Wet Lab Buildout Grant from Montgomery County Economic Development Corporation

Rockville, MD. Rise Therapeutics today announced that the Montgomery County Economic Development Corporation (MCEDC) Fund’s Bio Lab Pilot Project issued Rise Therapeutics funding to support its clinical GMP manufacturing infrastructure build out. This grant supports a key corporative initiative for Rise Therapeutics to expand its product development infrastructure in the microbiome space to include capabilities that enable the organization to more efficiently and cost effectively transition cutting-edge microbiome discoveries into clinically validated drug products. This MCEDC funding program supports $10 per square foot of lab fit out costs to build out wet lab space up to 5,000 square feet.

Rise Therapeutics Announces Publication of a New Article Related to its R-5780 Program

Rockville, MD. Rise Therapeutics, a biotechnology company developing first-in-class targeted immunological-based biologics using a unique and proprietary oral delivery platform, highlighted today a new publication in the journal Science that highlights mechanisms by which the microbiota engage host immune pathways to improve immunotherapy. The article examines recent pre-clinical studies that found that the peptidoglycan hydrolase Secrete Antigen A (SagA) is able to promote immunotherapy responses and synergize with immune checkpoint inhibitors (ICI) to drive tumor regression in animal model studies. These results support development of novel synthetic biology medicines to be used in conjunction with ICI therapy.

Rise Therapeutics Granted a Small Business Innovation Research Matching Grant from the Montgomery County

Rockville, MD. Rise Therapeutics today announced that Montgomery County has issued Rise Therapeutics a $25,000 Small Business Innovative Research (SBIR) grant matching award. This funding was awarded based upon Montgomery County’s SBIR/STTR Matching Grant Program and will be used to further Rise Therapeutics’ research project efforts to develop novel microbiome-based medicines,

Rise Therapeutics Hires Sathya Janardhanan, MS as Vice President of Development and Manufacturing

Rockville, MD. Rise Therapeutics, a synthetic biology company developing targeted immunological-based biologics using a unique and proprietary oral delivery platform, today announced the appointment of Sathya Janardhanan, MS, as Vice President of Development and Manufacturing.